Literature DB >> 29933438

Primary surgical repair of coarctation of the aorta in adolescents and adults: intermediate results and consequences of hypertension.

Bijoy G Rajbanshi1,2, Dikshya Joshi1, Sidhartha Pradhan1, Navin C Gautam1, Rabindra Timala1, Urmila Shakya3, Apurb Sharma4, Gangaram Biswakarma5, Jyotindra Sharma1.   

Abstract

OBJECTIVES: Coarctation of the aorta is known to present with hypertension in older patients; we reviewed our experience and assessed the outcome of hypertension following surgical correction.
METHODS: From April 2004 to date, 43 patients above the age of 12 underwent coarctation of the aorta repair. The mean age was 20.4 + 9.7 years (maximum 56 years); 21 (48.8%) were older than 18 years and 28 (65.1%) were men. Thirty (69.8%) patients had hypertension. Fourteen (32.6%) had a bicuspid aortic valve; 11 (25.6%) had patent ductus arteriosus; 6 (14%) had myxomatous mitral valve; 4 (9.3%) had ascending aortic aneurysms; and 2 (4.7%) had descending aneurysms.
RESULTS: Surgical correction included resection and interposition of a tube graft in 31 (72.1%), an end-to-end anastomosis in 6 (14%) and patch aortoplasty in 3 (7%). Three (7%) patients required an extra-anatomical bypass: 1 had a long segment coarctation of the aorta, and 2 had a Bentall procedure with an ascending-to-descending aortic bypass. Staged procedures were done for concomitant disease in 4 (9.3%). There was 1 death: a 56-year-old woman died of refractory ventricular fibrillation during surgery. Thirty (69.8%) patients were discharged with antihypertensive medication. At a follow-up of 2.8 ± 2.2 years (maximum 9.2 years), the number of hypertensive patients decreased (17/36; 47.2%) (P = 0.042). Univariable predictors for persistence of hypertension revealed the use of an interpositional tube graft for repair (odds ratio 13.855, confidence interval 0.000-0.001; P = 0.001) as an indicator, whereas there were no independent predictors for persistence of hypertension.
CONCLUSIONS: Surgical intervention is warranted irrespective of age and helps correct and control hypertension better; however, significant numbers of patients still require antihypertensive medication and regular monitoring. Intervention using an interposition tube graft may affect the prevalence of hypertension.

Entities:  

Year:  2019        PMID: 29933438     DOI: 10.1093/ejcts/ezy228

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

Review 1.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 2.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

3.  Persistent Hypertension and Left Ventricular Hypertrophy After Repair of Native Coarctation of Aorta in Adults.

Authors:  Alexander C Egbe; William R Miranda; Carole A Warnes; Crystal Bonnichsen; Juan Crestanello; Jason H Anderson; Heidi M Connolly
Journal:  Hypertension       Date:  2021-07-12       Impact factor: 9.897

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.